Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients
Author Information
Author(s): Caron Martine, Vigouroux Corinne, Bastard Jean-Philippe, Capeau Jacqueline
Primary Institution: Institut national de la santé et de la recherche médicale (Inserm)
Hypothesis
The study investigates the role of PPARγ-dependent pathways in adipocyte dysfunction and lipodystrophy caused by antiretroviral therapy in HIV-infected patients.
Conclusion
The study concludes that decreased PPARγ expression and function due to antiretroviral therapy play a central role in HIV-related lipodystrophy and its metabolic consequences.
Supporting Evidence
- Adverse effects of protease inhibitors and nucleoside reverse transcriptase inhibitors on adipocyte function were observed.
- PPARγ expression was found to be decreased in adipose tissue of HIV-infected patients under antiretroviral therapy.
- Treatment with PPARγ agonists showed potential to improve lipoatrophy in patients.
Takeaway
HIV medications can harm fat cells, leading to problems like fat loss and insulin resistance, but some treatments might help fix this.
Methodology
The study utilized in vitro and ex vivo analyses of adipocytes and adipose tissue samples from HIV-infected patients to assess the effects of antiretroviral therapy on PPARγ expression and function.
Limitations
The study primarily focuses on the effects of specific antiretroviral drugs and may not encompass all potential factors influencing lipodystrophy in HIV patients.
Participant Demographics
The study includes HIV-infected patients undergoing antiretroviral therapy, with a focus on those experiencing lipodystrophy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website